KR101269588B1 - Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit - Google Patents

Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit Download PDF

Info

Publication number
KR101269588B1
KR101269588B1 KR1020100099759A KR20100099759A KR101269588B1 KR 101269588 B1 KR101269588 B1 KR 101269588B1 KR 1020100099759 A KR1020100099759 A KR 1020100099759A KR 20100099759 A KR20100099759 A KR 20100099759A KR 101269588 B1 KR101269588 B1 KR 101269588B1
Authority
KR
South Korea
Prior art keywords
formula
iodophenyl
carbomethoxy
tropane
cit
Prior art date
Application number
KR1020100099759A
Other languages
Korean (ko)
Other versions
KR20120038156A (en
Inventor
지대윤
이병세
박상돈
지형민
성현주
Original Assignee
(주)퓨쳐켐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)퓨쳐켐 filed Critical (주)퓨쳐켐
Priority to KR1020100099759A priority Critical patent/KR101269588B1/en
Priority to PCT/KR2011/007210 priority patent/WO2012050315A2/en
Publication of KR20120038156A publication Critical patent/KR20120038156A/en
Application granted granted Critical
Publication of KR101269588B1 publication Critical patent/KR101269588B1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Abstract

FIELD OF THE INVENTION The present invention relates to azetidinium salts of N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane compounds, methods for their preparation and applications In more detail, N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane compound is dissolved in a polar solvent and heated to N- (3 Provided is a method for selectively preparing an azetidinium salt of a -sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane compound. It can be applied as an effective precursor for the production of diagnostic [ 18 F] FP-CIT for positron emission tomography.

Description

AZETIDINIUM SALT AS FP-CIT PRECURSOR, SELECTIVE PREPARATION METHOD THEREOF, AND SYNTHESIS OF FP-CIT}

FIELD OF THE INVENTION The present invention relates to azetidinium salts as FP-CIT precursors, selective preparation thereof and the synthesis of FP-CIT.

Dopamine is a catecholamine that acts as a neurotransmitter in the brains of various animals, including humans, and is known to be involved in various mental disorders. In patients with schizophrenia, dopamine-induced neurotransmission is increased, while dopamine-induced neurotransmission decreases Parkinson's disease, which is accompanied by dyskinesia.

Dopamine secreted at the end of presynaptic cells passes through a synapse and binds to a dopamine receptor located at the end of the nerve cell to transmit a signal, followed by dissociation from the receptor and located at the end of the systemic cell It is reabsorbed through the transporter. Dopamine receptors and transporters are widely distributed in the striatum located in the midbrain, and in patients with Parkinson's disease, the concentrations of transporters are significantly reduced compared to normal people. Therefore, researches on Parkinson's disease diagnostic drugs using compounds that bind strongly to the dopamine transporter have been continuously conducted. Positron emission tomography, a diagnostic imaging technique in the field of nuclear medicine using radioisotopes, is a very useful molecular imaging technique that can detect biochemical changes and diagnose diseases early. Among the various radioisotopes emitting positrons, fluorine-18 is the most studied because of its ease of mass production, low positron energy, high specific activity and moderate half-life of 110 minutes.

Fluorine-18 labeling compounds developed specifically for the diagnosis of Parkinson's disease by specifically binding to the striatum include [ 18 F] fallypride and [ 18 F] FESP, which bind to dopamine receptors. tropane derivatives have been reported with [ 18 F] FECNT, [ 18 F] FP-CIT, [ 18 F] LBT999 and the like.

Figure 112010066095999-pat00001

Figure 112010066095999-pat00002

Among these, [ 18 F] FP-CIT is known to be easy to synthesize, chemically stable, and give good human images. Therefore, many synthetic and clinical studies have been conducted, and it has been approved by the Korea Food and Drug Administration in Korea. It is used.

Figure 112010066095999-pat00003

In the case of the tertiary amine substituted with a propyl having a leaving group X at the terminal, it has been reported that an azetidinium salt having a tetracycle is formed through an intramolecular cyclization reaction as shown in the above figure. Nucleophilic substitution reactions have been reported (VR Gaertner, J. Org. Chem ., 33 (2), 523-530, 1968; HM Zacharis, J. Am. Chem. Soc ., 93 (12), 1935 -1938, 1971; A. Bakalarz, Tetrahedron , 55, 12211-12226, 1999; DO Kiesewetter , J. Labelled Compd . Radiopham ., 47, 953-969, 2004; WO 90/08131; F. Couty, O. David, F. Durrat, G. Evano, S. Lakhdar, J. Marrot, M. Vargas-Sanchez, Eur . J. Org . Chem . , 3479-3490, 2006.).

The present inventors observed that an additional polar compound is produced in the process of synthesizing and storing the FP-CIT precursor, and the separation / analysis confirmed that the compound is an azetidinium salt compound, and this is for preparing [ 18 F] FP-CIT. The present invention was completed by confirming that it could be a better precursor.

An object of the present invention is a precursor for the synthesis of N- (3-fluoropropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (hereinafter referred to as FP-CIT). It is to provide a novel azetidinium salt.

Another object of the present invention is to provide a novel formula 1 ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [azetidine-1, A method for preparing azetidinium salt represented by 8'-bicyclo [3.2.1] octane] -1- 옥 R-substituted sulfonate} with high purity.

Another object of the present invention is the nucleophilic fluorination reaction compared to the conventional precursor N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane It is shown to be a better compound.

In order to achieve the above object, the present invention provides an azetidinium salt represented by the following formula ( 1 ).

Figure 112010066095999-pat00004

(In Formula 1, R is C 1-6 alkyl or C 6-12 aryl, the alkyl group may be substituted or unsubstituted with halogen, the aryl group is C 1-3 alkyl, halogen, nitro (NO 2 May be substituted or unsubstituted)

* Compound name: ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [azetidine-1,8'-bicyclo [ 3.2.1] octane] -1- 윰 R-substituted sulfonate {( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [azetidine-1, 8'-bicyclo [3.2.1] octan] -1-ium R-substituted sulfonate}

In addition, the present invention provides a FP-CIT precursor represented by the following formula ( 1 ).

[Formula 1]

Figure 112010066095999-pat00005

(In Formula 1, R is C 1-6 alkyl or C 6-12 aryl, the alkyl group may be substituted or unsubstituted with halogen, the aryl group is C 1-3 alkyl, halogen, nitro (NO 2 May be substituted or unsubstituted)

In addition, the present invention provides a method for selectively preparing a compound represented by Chemical Formula 1 or Chemical Formula 2 using the polarity of the solvent, as shown in Scheme 1 below.

[Reaction Scheme 1]

Figure 112010066095999-pat00006

(In the above scheme 1, R is a C 1 -6 alkyl or C 6 -12 aryl, wherein the aryl group is C 1 -3 alkyl, halogen, the alkyl group may be unsubstituted or substituted by halogen, nitro (NO 2 May be substituted or unsubstituted)

In addition, the present invention provides a method for preparing FP-CIT represented by the formula ( 3) through a nucleophilic fluorination reaction using the azetidinium salt represented by the formula ( 1) , as shown in Scheme 2 below.

[Reaction Scheme 2]

Figure 112010066095999-pat00007

(In Scheme 2, R is C 1-6 alkyl or C 6-12 aryl, the alkyl group may be substituted or unsubstituted with halogen, the aryl group is C 1-3 alkyl, halogen, nitro (NO 2 May be substituted or unsubstituted, and F is 18 F or 19 F)

N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane, a precursor of [ 18 F] FP-CIT, has been used for chemical stability. This low, there was a disadvantage in that it is decomposed into various compounds during storage, the azetidinium salt according to the present invention can be prepared not only with high purity, but also has a high chemical stability characteristics that can be stored for a long time. In addition, FP-CIT can be synthesized at a much faster and higher yield in nucleophilic fluorination reaction, and thus can be useful for preparing [ 18 F] FP-CIT.

1 is a view showing a method for synthesizing a compound represented by Formula 1 and a reversible reaction with a compound represented by Formula 2 according to the present invention.
2 is a view showing the ratio of the compound of Formula 1a and the compound represented by Formula 2a according to the present invention are produced in various solvents.
3 is a diagram showing the ratio of the compound of Formula 1b and the compound represented by Formula 2b according to the present invention in various solvents.
4 is a graph in which the compound of Formula 1 according to the present invention is distributed according to the polarity of the solvent.
5 is a graph showing a nucleophilic fluorination reaction using the compound represented by the formula ( 2b ).
6 is a graph showing a nucleophilic fluorination reaction using a compound represented by Chemical Formula 1b according to the present invention.

Hereinafter, the present invention will be described in detail.

The present invention is formula 1 {( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [azetidine-1,8'- An azetidinium salt represented by bicyclo [3.2.1] octane] -1- 윰 R-substituted sulfonate}.

[Formula 1]

Figure 112010066095999-pat00008

In Formula 1, R is C 1-6 alkyl or C 6-12 aryl, the alkyl group may be substituted or unsubstituted with halogen, the aryl group is C 1-3 alkyl, halogen, nitro (NO 2 ) It may be substituted or unsubstituted with. Preferably, R is methyl, trifluoromethyl, phenyl, toluenyl, 4-bromophenyl, or 4-nitrophenyl, more preferably R is methyl or toluenyl.

In addition, the present invention provides a method for the selective preparation of a compound represented by Formula 1 or Formula 2 , as shown in Scheme 1.

[Reaction Scheme 1]

Figure 112010066095999-pat00009

In Scheme 1, R is as defined in the formula ( 1) .

According to the present invention, the azetidinium salt represented by the formula ( 1) is a compound represented by the formula (2) as in Scheme 1, that is, N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3- It may optionally be prepared from β- (4-iodophenyl) tropane.

In the method for preparing an azetidinium salt of the present invention, the reaction scheme 1 is organic N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropan It is a reaction that dissolves in a solvent and nucleophilic N-alkylation in a molecule. At this time, the organic solvent is E T N (normalized standard solvent polarity) may be used a polar solvent or higher value is 0.38, for example, dimethyl formamide (N, N-dimethylformamide, DMF), t - butanol, acetonitrile Reel, methanol, ethanol, isopropanol, dimethylsulfoxide (dimethylsulfoxide, DMSO), t -amyl alcohol, water and the like can be used, preferably acetonitrile, ethanol, methanol, t -butanol can be used. The standard value of E T N represents the polarity of the solvent is a value which defines a water 1.00, tetramethylsilane, 0.00 and measure the polarity of the solvent (as described in [Solvents and Solvent Effects in Organic Chemistry, 3 rd Edition, 2003, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim].

In addition, according to the present invention, the compound represented by Chemical Formula 2 may also be selectively prepared from an azetidinium salt represented by Chemical Formula 1 . In this case, a non-polar solvent having an E T N value of 0.20 or less may be used, and preferably benzene, toluene, diethyl ether, tetrahydrofuran, 1,4-dioxane, t -butyl methyl ether, dimethoxymethane , Diethoxymethane, carbon tetrachloride (CCl 4 ), and the like can be used.

Furthermore, the present invention provides a method for preparing FP-CIT through a nucleophilic fluorination reaction from the azetidinium salt represented by Chemical Formula 1 .

[Reaction Scheme 2]

Figure 112010066095999-pat00010

In Scheme 1, R is as defined in Formula 1, F is 19 F or 18 F.

The azetidinium salt represented by Formula 1 according to the present invention is a fluoro compound represented by Formula 3 by reacting with fluoride ions in an organic solvent as in Scheme 2, N- (3-fluoropropyl) -2-β. Carbomethoxy-3-β- (4-iodophenyl) tropane. In this case, acetonitrile, dimethylformamide, dimethyl sulfoxide and tertiary alcohols such as t -butanol and t -amyl alcohol may be used as the organic solvent. Preferably, t -butanol and t -amyl alcohol are used. Can be used.

Hereinafter, the present invention will be described in detail with reference to Examples and Experimental Examples. However, the following examples and experimental examples are only for the purpose of illustrating the present invention, and the content of the present invention is not limited by the following examples and experimental examples.

Preparation Example 1 Preparation of N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (compound of Formula 2)

Figure 112010066095999-pat00011

Step 1: Preparation of N- (3-hydroxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (5a)

nor-β-CIT ( 4 , 965 mg, 2.6 mmol) was dissolved in anhydrous toluene (60 mL) under argon gas, then 3-bromo-1-propanol (1.15 g, 8.3 mmol) and triethylamine (1.8 mL) ). The reaction mixture was heated to reflux for 4 hours, cooled to room temperature, the resulting solid was filtered off, and then toluene was removed under reduced pressure. Column chromatography with methanol / dichloromethane (8/92) gave the target compound N- (3-hydroxypropyl) -2-β-carbomethoxy-3-β- (4-iodo, a colorless liquid. Phenyl) tropane ( 5a , 1 g, 90%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.50-1.82 (m, 5H), 2.00-2.20 (m, 2H), 2.40-2.48 (m, 1H), 2.53 (td, 1H, J = 12.8, 2.9 Hz ), 2.54-2.64 (m, 1H), 2.87-2.92 (m, 1H), 2.94-3.03 (m, 1H), 3.50 (s, 3H), 3.59-3.67 (m, 2H), 3.75-3,80 (m, 2H), 6.97 (d, 2H, J = 8.2 Hz), 7.57 (d, 2H, J = 8.6 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 24.8, 26.3, 29.0, 33.6, 33.8, 51.4, 53.0, 54.6, 59.2, 64.5, 64.8, 91.3, 129.4, 136.4, 142.2, 172.1

Step 2-1: Preparation of N- (3-methanesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (2a)

N- (3-hydroxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 5a , 102 mg, 0.24 mmol) obtained in step 1 was dried under argon gas. After dissolving in dichloromethane (3 mL), anhydrous methanesulfonate (91 mg, 0.52 mmol) and diisopropylethylamine (34 mg, 0.26 mmol) were added sequentially. After stirring for 2 and a half hours at room temperature, dichloromethane was removed under reduced pressure, and column chromatography was carried out with diethyl ether / triethylamine (97/3) to give the title compound N- (3-methane as a colorless liquid. Sulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 2a , 114 mg, 94%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.60-1.88 (m, 5H), 1.94-2.15 (m, 2H), 2.30-2.42 (m, 2H), 2.50 (td, 1H, J = 12.4, 2.8 Hz ), 2.87-2.92 (m, 1H), 2.94-2.99 (m, 1H), 2.98 (s, 3H), 3.34-3.40 (m, 1H), 3.49 (s, 3H), 3.62-3.66 (m, 1H ), 4.24-4.38 (m, 2H), 6.99 (d, 2H, J = 8.4 Hz), 7.58 (d, 2H, J = 8.4 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 25.9, 26.0, 28.5, 33.8, 33.9, 37.0, 49.0, 51.1, 52.6, 61.5, 61.8, 62.8, 68.4, 91.1, 129.4, 136.9, 142.8, 171.9

Step 2-2: Preparation of N- (3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (2b)

N- (3-hydroxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 5a , 102 mg, 0.24 mmol) obtained in step 1 was dried under argon gas. After dissolving in dichloromethane (3 mL), anhydrous toluenesulfonate (171 mg, 0.52 mmol) and diisopropylethylamine (34 mg, 0.26 mmol) were added sequentially. After stirring for 2 and a half hours at room temperature, dichloromethane was removed under reduced pressure, and column chromatography was performed with diethyl ether / triethylamine (97/3) to give a colorless liquid target compound N- (3-toluene. Sulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 2b , 114 mg, 94%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.50-1.80 (m, 5H), 1.88-2.10 (m, 2H), 2.26 (t, 2H, J = 6.0 Hz), 2.30-2.40 (m, 1H), 2.45 (s, 3H), 2.80-2.94 (m, 2H), 3.18-3.25 (m, 1H), 3.41 (s, 3H), 3.54-3.60 (m, 1H), 4.05-4.20 (m, 2H), 6.96 (d, 2H, J = 8.0 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.57 (d, 2H, J = 8.4 Hz), 7.79 (d, 2H, J = 8.4 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 21.8, 26.0, 26.1, 28.7, 33.9, 33.9, 49.4, 51.1, 52.7, 61.6, 63.1, 91.2, 126.1, 128.1, 128.7, 129.1, 129.6, 130.0, 133.3, 137.0 , 137.7, 143.1, 144.7, 171.8

Experimental Example 1 According to the solvent of N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane according to the solvent Generation of azetidinium salts

Figure 112010066095999-pat00012

The present inventors N- (3- sulfonyloxy propyl) -2-methoxy-β- carbonyl -3-β- (4- iodo-phenyl) tropane compound of step 2 of Preparation Example 1, denoted by general formula (2) In the process of synthesizing and separating together, a more polar compound was found. In addition, the compound represented by the formula ( 2 ) was generated in a few hours at room temperature and low temperature of −20 ° C. even when the compound of high purity was separated and stored. It was observed to gradually increase its amount. Based on this, the change of the compound in the solvent having various polarities was measured quantitatively.

Azeti, a polar compound produced from N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane compounds 2a and 2b obtained in Preparation Example 1 To specifically synthesize the dinium salt, 2a and 2b compounds were synthesized as in Preparation Example 1, and then stored for 48 hours, and 5 mg of each was dissolved in various solvents (1 mL) listed in Table 1 below, and then at 70 ° C. Heat for 1 h and analyze the mixture by HPLC. The analysis results are as shown in Table 1 and FIGS. 2 and 3.

Solvent Methanesulfonate Toluenesulfonate 2a 1a 2b 1b Initial ratio before heating 30.2 69.8 74.6 25.4 toluene 96.5 3.5 93.5 6.5 benzene 94.7 5.3 92.4 7.6 Tetrahydrofuran 97.5 2.5 96.2 3.8 chloroform 73.9 26.1 72.8 27.2 Acetone 60.2 39.8 32.7 67.3 Dimethylformamide 6.1 93.9 0 100 t -butanol 8.4 91.6 19.9 80.1 Acetonitrile 3.0 97.0 0 100 Methanol 0 100 0 100

As shown in Table 1, N- (3-sulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane compound represented by Chemical Formula 2 obtained in Preparation Example 1 After 48 hours of synthesis, the measured HPLC results showed that the azetidinium salt compound 1a was present at 69.8% for the methanesulfonate compound 2a , while the azetidinium salt compound was used for the toluenesulfonate compound 2b . Phosphorus 1b was found to be present at 25.4%. This result shows that the methanesulfonate leaving group is easily dissociated as compared to the toluenesulfonate leaving group. As a result, N- (3-toluenesulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) It is shown that the plate 2b is relatively more stable.

In addition, the results of the distribution of the compound according to the solvent showed that the distribution ratio of the compound after the experiment was determined according to the polarity of the solvent used regardless of the distribution ratio of the compound before the experiment.

Scheme 1 represents a reversible reaction between the compounds represented by the formula ( 2) and 1 , the compound of formula ( 2 ) that is relatively non-polar in the non-polar solvent is stabilized by the solvent, the compound of formula ( 1 ) is relatively polar in the polar solvent Stabilized by Therefore, in the solvent having a moderate polarity, the compounds represented by Chemical Formulas 2 and 1 coexist in a constant ratio.

In the results of Table 1, in the case of toluene, benzene, and tetrahydrofuran, which are nonpolar solvents, a relatively nonpolar compound of Formula 2 is mainly formed, and a polar solvent of dimethylformamide, t -butanol, acetonitrile, and methanol is used. It can be seen that the relatively polar azetidinium salt of Formula 1 is formed. In addition, it can be seen that the compounds represented by Chemical Formulas 2 and 1 co-exist in the case of chloroform and acetone solvent having moderate polarity.

The results of Table 1 are listed according to E T N (the water is defined as 1.00, the tetramethylsilane is defined as 0.00 and the solvent is measured), which is a standard value representing the polarity of the solvent. Figure 4 is a graph showing the production rate of the azetidinium salt compound according to the polarity value of the solvent.

Solvent E T N 1a 1b toluene 0.099 3.5 6.5 benzene 0.111 5.3 7.6 Tetrahydrofuran 0.207 2.5 3.8 chloroform 0.259 26.1 27.2 Acetone 0.355 39.8 67.3 Dimethylformamide 0.386 93.9 100 t -butanol 0.389 91.6 80.1 Acetonitrile 0.460 97.0 100 Methanol 0.762 100 100

In addition, as shown in Scheme 1, it can be seen that in the nonpolar solvent, the azetidinium salt compound represented by Chemical Formula 1 becomes a compound represented by Chemical Formula 2 by ring opening reaction of a tetragonal ring by nucleophilic attack of sulfonate anion. have. This has not been reported as a nucleophilic substitution reaction by a sulfonate anion which is known to have no nucleophilicity.

< Example  1> Azetidinium  Preparation of Salt (1a)

N- (3-methanesulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 2a ) obtained in step 2-1 of Preparation Example 1 was acetonite. After dissolving in a reel, the mixture was heated at 70 DEG C for 30 minutes and then the solvent was removed under reduced pressure. Again, it was dissolved in a small amount of dichloromethane, and then added with an excess of diethyl ether and centrifuged to give the white solid target compound azetidinium salt ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-IO Dophenyl) -2 '-(methoxycarbonyl) spiro [azetidine-1,8'-bicyclo [3.2.1] octane] -1-' methanesulfonate ( 1a ) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.93-2.18 (m, 3H), 2.35-2.58 (m, 3H), 2.74 (s, 3H), 2.75-2.90 (m, 2H), 3.14-3.22 (m , 1H), 3.23-3.30 (m, 1H), 3.57 (s, 3H), 4.16-4.25 (m, 1H), 4.25-4.33 (m, 1H), 4.55-4.67 (m, 2H), 4.78-4.90 (m, 2H), 6.98 (d, 2H, J = 8.4 Hz), 7.60 (d, 2H, J = 8.4 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 14.9, 23.0, 24.7, 27.1, 31.3, 39.6, 48.8, 52.6, 56.3, 64.3, 65.4, 68.1, 92.5, 129.0, 137.5, 138.6, 170.3

< Example  2> Azetidinium  Preparation of Salt (1b)

N- (3-toluenesulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 2a ) obtained in step 2-2 of Preparation Example 1 was obtained by acetonite. After dissolving in a reel, the mixture was heated at 70 DEG C for 30 minutes and then the solvent was removed under reduced pressure. After dissolving again in a small amount of dichloromethane, excess diethyl ether was added and centrifuged to give a white solid target compound azetidinium salt ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodo Phenyl) -2 '-(methoxycarbonyl) spiro [azetidine-1,8'-bicyclo [3.2.1] octane] -1-' toluenesulfonate ( 1b ) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.84-2.14 (m, 3H), 2.33 (s, 3H), 2.36-2.50 (m, 3H), 2.70-2.82 (m, 2H), 3.12-3.26 (m , 2H), 3.48 (s, 3H), 4.13-4.28 (m, 2H), 4.50-4.62 (m, 2H), 4.74-4.84 (m, 2H), 6.93 (d, 2H, J = 8.4 Hz), 7.13 (d, 2H, J = 8.4 Hz), 7.56 (d, 2H, J = 8.4 Hz), 7.76 (d, 2H, J = 8.4 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 14.9, 21.3, 23.0, 24.6, 27.0, 31.3, 48.8, 52.4, 56.2, 64.3, 65.4, 68.2, 92.3, 125.9, 128.6, 129.0, 137.4, 138.7, 139.2, 144.1 , 170.3

In addition, the present invention carried out an experiment to confirm that the compounds represented by the formula 1 and 2 are mutually converted according to the reaction scheme 1 and provides the results.

< Manufacturing example  2> 1,1- Die deuterium -3- ( Tetrahydropyranyloxy )profile Methanesulphone Preparation of Yite (9)

Figure 112010066095999-pat00013

Step 1: t -Butyl 3- ( Tetrahydropyranyloxy ) Propionate  (7)

t -butyl 3-hydroxypropionate ( 6 , 206 mg, 1.41 mmol) was dissolved in dichloromethane (9 mL) and then 3,4-dihydro-2 H -pyran (DHP, 142 mg, 1.69 mmol) ) And p -toluenesulfonic acid (14 mg, 0.07 mmol) were added and stirred at room temperature for 10 minutes. Saturated aqueous sodium hydrogen carbonate solution was added and the organic compound produced with dichloromethane was extracted. Then, column chromatography was carried out with ethyl acetate / n -hexane (1/9) to give the title compound t -butyl 3- (tetrahydro) as a colorless liquid. Pyranyloxy) propionate ( 7 , 324 mg, 99%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.46 (s, 9H), 1.48-1.62 (m, 4H), 1.65-1.73 (m, 1H), 1.76-1.86 (m, 1H), 2.51 (t, 2H , J = 6.4 Hz), 3.48-3.55 (m, 1H), 3.65 (dt, 1H, J = 6.4, 10.0 Hz), 3.84-3.91 (m, 1H), 3.96 (dt, 1H, J = 6.4, 10.0 Hz), 4.63 (t, 1 H, J = 3.6 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 19.3, 25.4, 28.1, 30.5, 36.4, 62.0, 63.3, 80.4, 98.7, 171.0

Step 2: 1,1- Die deuterium -3- ( Tetrahydropyranyloxy ) Propanol  (8)

The t -butyl 3- (tetrahydropyranyloxy) propionate ( 7 , 324 mg, 1.41 mmol) obtained in step 1 was dissolved in tetrahydrofuran (4 mL), and then LiAlD 4 (4.22 mL, 1.0 M tetrahydrofuran solution, 4.22 mmol) was slowly added dropwise. Water (0.2 mL) was added to terminate the reaction, 15% aqueous sodium hydroxide solution (0.2 mL) and water (0.6 mL) were added dropwise, and the resulting solid was filtered through a pad of silica gel. The solvent was removed under reduced pressure to obtain the title compound 1,1-dihydrogen-3- (tetrahydropyranyloxy) propanol ( 8 , 220 mg, 96%) as a colorless liquid.

1 H NMR (400 MHz, CDCl 3 ) δ 1.50-1.62 (m, 4H), 1.69-1.90 (m, 4H), 2.34 (brs, 1H), 3.50-3.56 (m, 1H), 3.58-3.64 (m , 1H), 3.84-3.91 (m, 1H), 3.91-3.98 (m, 1H), 4.58-4.62 (m, 1H); 13 C NMR (100 MHz, CDCl 3 ) δ 19.6, 25.3, 30.6, 31.8, 62.5, 66.4, 99.1.

Step 3: 1,1- Die deuterium -3- ( Tetrahydropyranyloxy )profile Methanesulfonei Manufacture of meth 9

1,1-dihydrogen-3- (tetrahydropyranyloxy) propanol ( 8 , 216 mg, 1.33 mmol) was dissolved in dichloromethane (5 mL), to which triethylamine (162 mg, 1.60 mmol) and methanesulfonyl chloride (183 mg, 1.60 mmol) were added dropwise sequentially at 0 ° C. After the reaction mixture was stirred at room temperature for 30 minutes, saturated aqueous sodium hydrogen carbonate solution was added, and the organic compound produced by dichloromethane was extracted, and then filtered through a pad of silica gel. The solvent was removed under reduced pressure to obtain the title compound 1,1-dihydrogen-3- (tetrahydropyranyloxy) propyl methanesulfonate ( 9 , 294 mg, 92%) as a yellow liquid.

1 H NMR (400 MHz, CDCl 3 ) δ 1.49-1.60 (m, 4H), 1.70-1.86 (m, 2H), 1.95-2.05 (m, 2H), 2.99-3.04 (d, 3H), 3.48-3.55 (m, 2H), 3.78-3.90 (m, 2H), 4.56-4.60 (m, 1H); 13 C NMR (100 MHz, CDCl 3 ) δ 19.6, 25.4, 29.3, 30.6, 31.6, 37.3, 62.5, 62.8, 99.1

Example 3 Preparation of N- (1,1-dideuterium-3-toluenesulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (2c)

Figure 112010066095999-pat00014

Step 1: Preparation of N- (1,1-dihydrogen-3-tetrahydropyranyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (10)

nor-β-CIT ( 4 , 100 mg, 0.27 mmol) was dissolved in anhydrous acetonitrile (5 mL) under argon gas, and then 1,1-dihydrogen-3- (tetrahydropyranyl) obtained in Preparation Example 2 Oxy) propyl methanesulfonate ( 9 , 78 mg, 0.32 mmol) and diisopropylethylamine (52 mg, 0.4 mmol) were added dropwise sequentially. The reaction mixture was heated at 80 ° C. for 5 hours and then the acetonitrile was removed under reduced pressure. Column chromatography with diethyl ether / n -hexane / triethylamine (40/60/1) gave the target compound N- (1,1-dihydrogen-3-tetrahydropyranyloxypropyl) as a colorless liquid. -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 10 , 98 mg, 71%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.46-1.88 (m, 9H), 1.94-2.14 (m, 2H), 2.52 (tt, 1H, J = 12.4, 2.8 Hz), 2.84-2.89 (m, 1H ), 2.89-2.97 (m, 1H), 3.35-3.40 (m, 1H), 3.40-3.47 (m, 2H), 3.49 (d, 3H, J = 4.0 Hz), 3.66-3.70 (m, 1H), 3.70-3.80 (m, 1H), 3.80-3.90 (m, 1H), 4.50-4.56 (m, 1H), 7.00 (d, 2H, J = 7.2 Hz), 7.57 (d, 2H, J = 8.0 Hz) ; 13 C NMR (100 MHz, CDCl 3 ) δ 19.9, 20.0, 25.6, 25.95, 25.97, 26.2, 29.2, 29.3, 30.93, 30.94, 34.00, 34.01, 34.04, 34.05, 51.1, 51.2, 52.8, 52.9, 61.7, 61.8 , 62.5, 62.7, 62.8, 65.7, 65.9, 91.11, 91.12, 99.0, 99.3, 129.61, 129.62, 137.0, 143.29, 143.30, 171.96, 172.01

Step 2: Preparation of N- (1,1-dihydrogen-3-hydroxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (5b)

N- (1,1-dideuterium-3-tetrahydropyranyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane obtained in step 1 ( 10 , 60 mg, 0.12 mmol) was dissolved in methanol (2 mL), and then p -toluenesulfonic acid (27 mg, 0.14 mmol) was added dropwise, followed by stirring at room temperature for 1 hour. Methanol was removed under reduced pressure, column chromatography was carried out with diethyl ether / triethylamine (97/3) to give the title compound N- (1,1-dihydrogen-3-hydroxypropyl) -2 as a colorless liquid. -β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 5b , 55 mg, 74%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.47-1.75 (m, 1H), 1.78-1.80 (m, 4H), 1.98-2.18 (m, 2H), 2.51 (td, 1H, J = 12.8, 2.8 Hz ), 2.86-2.90 (m, 1H), 2.93-3.02 (m, 1H), 3.48 (s, 3H), 3.56-3.66 (m, 2H), 3.70-3.82 (m, 2H), 6.96 (d, 2H) , J = 8.4 Hz), 7.55 (d, 2H, J = 8.0 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 25.0, 26.5, 28.9, 33.7, 33.9, 51.5, 53.1, 59.3, 64.5, 64.8, 91.4, 129.5, 137.1, 142.3, 172.2

Step 3: Preparation of N- (1,1-dideuterium-3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (2c)

N- (1,1-dihydrogen-3-hydroxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane obtained in step 2 ( 5b , 50 mg, 0.12 mmol) was dissolved in anhydrous dichloromethane (1.2 mL) under argon gas, followed by anhydrous toluenesulfonate (83 mg, 0.26 mmol) and diisopropylethylamine (17 mg, 0.13 mmol). After stirring for 3 hours at room temperature, dichloromethane was removed under reduced pressure, and column chromatography was performed with diethyl ether / n -hexane / triethylamine (50/50/1) to give a colorless liquid N. -(1,1-dideuterium-3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 2c , 55 mg, 81%) was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.50-1.74 (m, 5H), 1.86-2.80 (m, 2H), 2.34 (td, 2H, J = 12.4, 2.8 Hz), 2.45 (s, 3H), 2.80-2.94 (m, 2H), 3.18-3.25 (m, 1H), 3.40 (s, 3H), 3.54-3.60 (m, 1H), 4.04-4.18 (m, 2H), 6.96 (d, 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.56 (d, 2H, J = 8.4 Hz), 7.79 (d, 2H, J = 8.4 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 21.7, 25.8, 26.0, 28.4, 33.7, 33.8, 51.0, 52.5, 61.4, 62.9, 68.9, 91.0, 125.9, 127.9, 128.6, 128.9, 129.4, 129.8, 133.2, 136.8 , 137.5, 142.9, 144.6, 171.7

Experimental Example 2 N- (1,1-dideuterium-3-toluenesulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (2c) and its Reversible Reaction with Azetidinium Salts (1c)

Figure 112010066095999-pat00015

Step 1: Azetidinium salt of N- (1,1-dideuterium-3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (1c) Manufacture

N- (1,1-dideuterium-3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane obtained in Example 3 ( 2c , 55 mg) , 0.1 mmol) was dissolved in acetonitrile (8 mL), heated at 70 ° C. for 30 minutes, and then acetonitrile was removed under reduced pressure. After dissolving in a small amount of dichloromethane, excess diethyl ether was added and centrifuged to give a white solid target compound azetidinium salt ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl ) -2 '-(methoxycarbonyl) spiro [2,2-dihydrogenazetidine-1,8'-bicyclo [3.2.1] octane] -1- 윰 toluenesulfonate ( 1c , 53 mg, 96%).

1 H NMR (400 MHz, CDCl 3 ) δ 1.82-2.00 (m, 2H), 2.04-2.14 (m, 1H), 2.32 (s, 3H), 2.34-2.46 (m, 3H), 2.67-2.80 (m , 2H), 3.12-3.25 (m, 2H), 3.47 (s, 3H), 4.18-4.26 (td, 1H, J = 10.0, 4.0 Hz), 4.46-4.62 (m, 2H), 4.70-4.78 (m , 1H), 6.92 (d, 2H, J = 8.4 Hz), 7.12 (d, 2H, J = 8.0 Hz), 7.54 (d, 2H, J = 8.4 Hz), 7.75 (d, 2H, J = 8.0 Hz ); 13 C NMR (100 MHz, CDCl 3 ) δ 14.7, 21.4, 23.1, 24.7, 27.1, 31.3, 48.8, 52.5, 56.3, 65.4, 68.2, 92.4, 126.0, 128.7, 129.1, 137.5, 138.9, 139.3, 144.2, 170.4

Step 2: Azetidinium  Of salt (1c) Ring opening  reaction

Azetidinium salt obtained in step 1 ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [2,2-dihydrogen Azetidine-1,8′-bicyclo [3.2.1] octane] -1- 윰 toluenesulfonate ( 1c , 40 mg) was dissolved in benzene (10 mL), heated at 70 ° C. for 1 hour, benzene was removed under reduced pressure, and NMR spectrum was obtained.

1 H NMR (400 MHz, CDCl 3 ) δ 1.50-1.76 (m, 5H), 1.86-2.10 (m, 2H), 2.22-2.28 (m, 1H), 2.30-2.40 (m, 1H), 2.45 (s , 3H), 2.78-2.94 (m, 2H), 3.16-3.26 (m, 1H), 3.40 (s, 3H), 3.53-3.60 (m, 1H), 4.04-4.18 (m, 1H), 6.96 (d , 2H, J = 8.4 Hz), 7.35 (d, 2H, J = 8.0 Hz), 7.56 (d, 2H, J = 8.0 Hz), 7.79 (d, 2H, J = 7.6 Hz); 13 C NMR (100 MHz, CDCl 3 ) δ 21.8, 26.0, 26.1, 28.5, 33.8, 33.9, 49.4, 51.1, 52.7, 52.8, 61.5, 61.6, 63.03, 63.07, 69.0, 91.2, 126.1, 128.0, 128.7, 129.0 , 129.5, 130.0, 137.0, 137.6, 143.1, 144.7, 171.8

In Experimental Example 2, an azetidinium salt ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro, which is the target compound of step 1 [2,2-dideuterium azetidine-1,8'-bicyclo [3.2.1] octane] -1- 윰 toluenesulfonate ( 1c ) shows an NMR spectrum indicating that only one of the two expected compounds is produced. The ring opening reaction was performed in a non-polar benzene solvent in step 2, and the NMR spectrum was confirmed. N- (1,1-dihydrogen-3-toluenesulfonoxypropyl) -2-β-carbomethoxy- 3-β- (4-iodophenyl) tropane ( 2c ) and N- (3,3-dideuterium-3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4- It was found that iodophenyl) tropane ( 2d ) was produced as a mixture ( 2c : 2d = 61:39). This clearly confirmed that the polar compound produced in step 1 was an azetidinium salt, and proved that a reversible reaction between the compounds represented by Formulas 2 and 1 occurred.

<Experiment 3> N- (3-toluenesulfonyloxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane (2b) and azetidinium (1b) Nuclear fluorination reaction

Figure 112010066095999-pat00016

N- (3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ( 2b ) and azetidinium obtained in step 2-2 of Preparation Example 1 The nucleophilic fluorination reaction with salt ( 1b ) was carried out. At this time, the precursor compounds 2b and 1b were used each 5 mg (0.0086 mmol), the reaction solvent was used t -butanol (1 mL). Tetra- n -butylammonium fluoride (TBAF) was used 5 mg (0.0172 mmol) each, and reacted at 80 ° C. for 30 minutes.

t - Butanol  In solvent Nucleophilic  Substitution reaction

Using t -butanol as a solvent, the reaction mixture was taken at 5, 10, 15, 20 and 30 minutes and analyzed by HPLC, and the results are shown in Table 3 below and FIGS. 5 and 6.

Time (minutes) 2b 1b 2b 1b 3 11 2b 1b 3 11 5 37.6 1.8 11.9 48.7 0 1.8 51.2 47.0 10 17.3 2.3 19.3 61.1 0 1.8 51.3 46.9 15 8.0 2.3 23.2 66.5 0 1.8 52.2 46.0 20 4.4 2.4 25.0 68.2 - - - - 30 2.4 2.2 27.2 68.2 0 1.7 53.1 45.2

As shown in Table 3, in the case of N- (3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane represented by Formula 2b , for 30 minutes It can be seen that the reaction takes place slowly, and after 30 minutes, the product represented by the formula (3) is obtained at 27.2%, whereas the adduct of the formula (11) is rapidly formed at the beginning of the reaction, reaching 68.2% after 30 minutes. .

In addition, in the case of an azetidinium salt of N- (3-toluenesulfonoxypropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane represented by the formula (1b) according to the present invention, The reaction was terminated in 5 minutes and 51.2% of product was obtained.

Thus, it was found that tertiary alcohol solvents such as t -butanol were effective for nucleophilic fluorination reactions using the azetidinium salt precursors of the present invention, and N- (3-toluenesulfonoxypropyl) -2-β-carbome Compared to the nucleophilic fluorination reaction of the oxy-3-β- (4-iodophenyl) tropane ( 2b ) precursor, the azetidinium salt represented by the general formula ( 1b ) according to the present invention is 7 times faster and about 2 times faster. It can be seen that the high yield.

Claims (16)

Formula 1 ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [azetidine-1,8'-bicyclo [3.2 .1] azetidinium salt represented by: octane] -1- 윰 R-substituted sulfonate):
[Formula 1]
Figure 112012066617283-pat00017

(In Formula 1, R is methyl, trifluoromethyl, phenyl, toluenyl, 4-bromophenyl, or 4-nitrophenyl) The azetidinium salt of claim 1, wherein R is methyl or toluenyl. Formula 1 ( 1'R, 2'S, 3'S, 5'S ) -3 '-(4-iodophenyl) -2'-(methoxycarbonyl) spiro [azetidine-1,8'-bicyclo [3.2 N- (3- [ 18 F] fluoropropyl) -2-β-carbomethoxy-3-β- (4 for diagnosing Parkinson's disease, designated .1] octane] -1-] R-substituted sulfonate) Precursors of iodophenyl) tropane ([ 18 F] FP-CIT):
[Formula 1]
Figure 112013000916284-pat00018

(In Formula 1, R is methyl, trifluoromethyl, phenyl, toluenyl, 4-bromophenyl, or 4-nitrophenyl) 4. The N- (3- [ 18 F] fluoropropyl) -2-β-carbomethoxy-3-β- (4-iodo according to claim 3, wherein R is methyl or toluenyl. Phenyl) tropane ([ 18 F] FP-CIT). As shown in Scheme 1, a method for selectively preparing a compound represented by Chemical Formula 1 using a polar solvent, comprising dissolving the compound represented by Chemical Formula 2 in a polar solvent:
[Reaction Scheme 1]
Figure 112012066617283-pat00027

(In Scheme 1, R is methyl, trifluoromethyl, phenyl, toluenyl, 4-bromophenyl, or 4-nitrophenyl) 6. The method of claim 5, represented by the formula (1), characterized in that for selectively producing a compound represented by the formula (1) using a polar solvent, or more levels of 0.38 E T N (normalized standard solvent polarity) from the compound represented by the following formula (2) Selective Preparation of Compounds. 6. The polar solvent according to claim 5, wherein the polar solvent is one selected from the group consisting of dimethylformamide, t -butanol, acetonitrile, methanol, ethanol, isopropanol, dimethyl sulfoxide, t -amyl alcohol and water. Selective preparation method of a compound represented by the formula (1). The method of claim 5, wherein the compound represented by Chemical Formula 2 is added to a polar solvent and heated at 70 ° C. for 1 hour. delete delete delete delete To, as shown in Scheme 2, T kinase pyridinium salt represented by formula 1 (1'R, 2'S, 3 'S, 5'S) -3 '- (4- iodo-phenyl) -2' - (methoxycarbonyl) Spy N- (expressed by Formula 3 , including nucleophilic fluorination reaction using rho [azetidine-1,8'-bicyclo [3.2.1] octane] -1- 윰 R-substituted sulfonate) Preparation of 3- [ 18 F] fluoropropyl) -2-β-carbomethoxy-3-β- (4-iodophenyl) tropane ([ 18 F] FP-CIT):
[Reaction Scheme 2]
Figure 112013000916284-pat00028

(In Scheme 2, R is methyl, trifluoromethyl, phenyl, toluenyl, 4-bromophenyl, or 4-nitrophenyl) 14. The method of claim 13, wherein the organic solvent used for the nucleophilic fluorination reaction is (a 3- [18 F] fluoro-propyl) N- wherein one member is selected from the group consisting of tertiary alcohols -2-β Method for preparing carbomethoxy-3-β- (4-iodophenyl) tropane ([ 18 F] FP-CIT). The N- (3- [ 18 F] fluoropropyl) -2-β-carbomethoxy-3-β-, wherein the tertiary alcohol is t -butanol or t -amyl alcohol. Method for preparing (4-iodophenyl) tropane ([ 18 F] FP-CIT). The N- (3- [ 18 F] fluoropropyl) -2-β according to claim 13, wherein 18 F − in Scheme 2 uses tetra-n-butylammonium [ 18 F] fluoride. Method for preparing carbomethoxy-3-β- (4-iodophenyl) tropane ([ 18 F] FP-CIT).
KR1020100099759A 2010-10-13 2010-10-13 Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit KR101269588B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020100099759A KR101269588B1 (en) 2010-10-13 2010-10-13 Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit
PCT/KR2011/007210 WO2012050315A2 (en) 2010-10-13 2011-09-30 Azetidinium salt as fp-cit precursor, method for selectively preparing same, and fp-cit synthesis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020100099759A KR101269588B1 (en) 2010-10-13 2010-10-13 Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit

Publications (2)

Publication Number Publication Date
KR20120038156A KR20120038156A (en) 2012-04-23
KR101269588B1 true KR101269588B1 (en) 2013-06-05

Family

ID=45938770

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020100099759A KR101269588B1 (en) 2010-10-13 2010-10-13 Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit

Country Status (2)

Country Link
KR (1) KR101269588B1 (en)
WO (1) WO2012050315A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111909159A (en) * 2019-05-08 2020-11-10 成都弘达药业有限公司 Epipiprazole related substance and preparation method thereof
CN113024542B (en) * 2021-03-11 2022-01-14 江苏省原子医学研究所 Deuterated tropane derivative and application thereof
CN114487184B (en) * 2022-01-21 2023-09-22 江苏省原子医学研究所 Method for determining 2 beta-methyl ester-3 beta- (4-chlorophenyl) tropane and related substances thereof
KR20230159083A (en) * 2022-05-13 2023-11-21 (주)듀켐바이오 Manufacturing method for fp-cit precursor and manufacturing method for [18f]fp-cit using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090257949A1 (en) 2008-04-04 2009-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical Imaging of Neurodegenerative Diseases
US20100113763A1 (en) 2004-12-15 2010-05-06 Futurechem Co., Ltd. Method for preparation of organofluoro compounds in alcohol solvents
US20100256389A1 (en) 2007-12-07 2010-10-07 Franziska Wagner Method for producing precursors for l-2- [18f] fluorophenylalanine and 6- [18f] fluoro-l--meta-tyrosine and the alpha-methylated derivatives thereof, precursor, and method for producing l-2- [18f] fluorophenylalanine and 6- [18f] fluoro-l-meta-tyrosine and the alpha-methylated derivatives from the precursor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113763A1 (en) 2004-12-15 2010-05-06 Futurechem Co., Ltd. Method for preparation of organofluoro compounds in alcohol solvents
US20100256389A1 (en) 2007-12-07 2010-10-07 Franziska Wagner Method for producing precursors for l-2- [18f] fluorophenylalanine and 6- [18f] fluoro-l--meta-tyrosine and the alpha-methylated derivatives thereof, precursor, and method for producing l-2- [18f] fluorophenylalanine and 6- [18f] fluoro-l-meta-tyrosine and the alpha-methylated derivatives from the precursor
US20090257949A1 (en) 2008-04-04 2009-10-15 Avid Radiopharmaceuticals, Inc. Radiopharmaceutical Imaging of Neurodegenerative Diseases

Also Published As

Publication number Publication date
WO2012050315A2 (en) 2012-04-19
WO2012050315A3 (en) 2012-06-14
KR20120038156A (en) 2012-04-23

Similar Documents

Publication Publication Date Title
RU2754536C1 (en) Magl inhibitors
CN103097364B (en) As the spiro-piperidine derivatives of S1P conditioning agent
AU2008340182A1 (en) Translocator protein ligands
KR101269588B1 (en) Azetidinium salt as fp-cit precursor, selective preparation method thereof, and synthesis of fp-cit
PT2342205T (en) Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
KR102150739B1 (en) Carbamate/urea derivatives
US20220306569A1 (en) Crystalline forms of hydroxynorketamine
RU2700796C2 (en) Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine
JP5875863B2 (en) Anhydrous crystalline form of orbupitant maleate
BR112020018158A2 (en) adenosine receptor antagonists and uses thereof
ES2729490T3 (en) Isoindoline derivatives
JP2011509933A (en) Preparation and enantiomeric separation of 7- (3-pyridinyl) -1,7-diazaspiro [4.4] nonane and new salt forms of its racemates and enantiomers
CN109879934A (en) A kind of salt and preparation method thereof of phenylpropionyl amine derivant
KR20170033684A (en) Crystalline form of linagliptin and preparation method thereof
EP0546389A1 (en) Piperidylmethyl substituted chroman derivatives as agents for the treatment of diseases of the central nervous system
US20090076027A1 (en) Deuterium-enriched lurasidone
EP4219485A1 (en) Fused tricyclic derivative and pharmaceutical application thereof
Liu et al. Diastereoselective Synthesis of Functionalized Tetrahydropyrimidin‐2‐thiones via ZnCl2 Promoted One‐pot Reactions
KR101781352B1 (en) Crystalline forms of novel varenicline salts, preparation methods thereof and pharmaceutical compositions comprising thereof
TW202330534A (en) Fused pyrazole ring compound and application thereof
US20080299217A1 (en) Deuterium-enriched bifeprunox
US20090076165A1 (en) Deuterium-enriched memantine
KR20230005893A (en) Lumen acting N-(piperidin-4-yl)benzamide derivatives
US20090062392A1 (en) Deuterium-enriched gabapentin
JP2021511375A (en) Crystal form, salt form and method for producing the tricyclic compound

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E90F Notification of reason for final refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20160426

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20170511

Year of fee payment: 5

FPAY Annual fee payment

Payment date: 20180515

Year of fee payment: 6